Global Erythropoietin (EPO) Drugs Market Professional Survey Report 2019
EPO is a naturally occurring hormone produced by cells in the kidneys that regulate the production of red blood cells in bone marrow.
Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.
The global Erythropoietin (EPO) Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Erythropoietin (EPO) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Erythropoietin (EPO) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Erythropoietin (EPO) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Erythropoietin (EPO) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Segment by Application
Anemia
Kidney Disorders
Other
Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.
The global Erythropoietin (EPO) Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Erythropoietin (EPO) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Erythropoietin (EPO) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Erythropoietin (EPO) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Erythropoietin (EPO) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Segment by Application
Anemia
Kidney Disorders
Other
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
